Department of the Army awards $1.15 million for small business research and development to Tessellated
The U.S. Army selected Tessellated to receive a Small Business Technology Transfer (STTR) Phase II contract to develop technologies that address military modernization challenges. The contract was awarded under the U.S. Army STTR program, which encourages small, high-tech, U.S.-based businesses (in partnership with major research institutions) to provide cutting-edge research and development solutions in response to critical defense needs. As with many agile technology companies, Tessellated is uniquely positioned to address the U.S. Army's modernization priorities.
Tessellated seeks to commercialize a high-strength polymer film discovered in the College of Engineering at the University of Notre Dame. This advanced material has a wide range of possible use cases and is application agnostic, including ballistic armor, thermal management and implementation in composite parts for aerospace and automotive applications.
Federal SBIR and STTR programs are known as "America's Seed Fund," enabling early-stage startups to develop critical technologies further and bring them to market. They are one of the largest sources of early-stage capital for technology commercialization in the United States. They meet federal research and development demand while increasing the potential for private-sector commercialization.
Central to the STTR program is the partnership between small businesses and nonprofit research institutions, catalyzing formal collaboration throughout Phase I and II development. According to SBIR.gov, STTR's most important role is to bridge the gap between basic science performance and the resulting innovations' commercialization.
In 2022 alone, Tessellated received three SBIR/STTR awards from the Department of Defense and the Department of Energy. The aggregate funding under these awards totals more than $500,000, with Notre Dame Research benefiting $167,000 in sub-awards as part of the STTR program.
According to Tessellated's CEO, Kevin Craig, "These non-dilutive awards coupled with local matching funds will allow Tessellated to continue to develop further innovations and chart a course toward scaled production. We will begin distributing material to our first customers and development partners in 2023."
For more information about Tessellated, visit tessellatedinc.com.
Originally published by ideacenter.nd.edu on March 21.
atLatest Research
- ‘The border between the secular and sacred:’ Anthropologist receives Templeton grant for research on psychedelics, mental health, and spiritual yearningAidan Seale-Feldman, an assistant professor in the Department of Anthropology, will lead a group of interdisciplinary researchers to work on the…
- South Bend is vulnerable to lead poisoning — here’s how ND-LIT can helpHeidi Beidinger is passionate about science and public health which has fueled her nearly 10-year crusade to get children tested for lead poisoning and help their families remediate lead found in and around their homes.…
- Engineers seek “switchable” materials to power next-generation microelectronicshris Hinkle is on the hunt for new materials. He needs them to power faster, smaller and more efficient chips for next-generation microelectronics, so only materials with the right chemistry and structure will do. “Current materials are not able to keep up with the growing needs for very tightly packed components,” said Hinkle, Leonard C. Bettex Professor of Electrical Engineering at the University of Notre Dame. “The materials used previously are simply falling short of performance requirements.” Hinkle, who is principal investigator on a new NSF-funded, multi-institutional semiconductor project, is looking for “switchable” semiconductor materials that can either conduct or impede the flow of electricity when activated by an external trigger.
- Cancer therapies show promise in combating tuberculosisA study from the University of Notre Dame, Massachusetts General Hospital and the National Institutes of Health has identified a combination of medications that may improve blood flow within granulomas, benefiting drug delivery. Published in the Proceedings of the National Academy of Sciences, the study leverages decades of cancer research to study tuberculosis-affected lung tissue and improve treatment.
- Notre Dame as a leading research universityThe University of Notre Dame has experienced transformational growth in research over the past decade. The evidence is everywhere on campus, both in the talent of the faculty and the resources devoted to making Notre Dame a leading research institution. In this episode of Notre Dame Stories,…
- Notre Dame faculty conduct translational research to address tuberculosis in lung cellsFor over 8,000 years, the “white death,” tuberculosis (TB), has plagued humankind. Its effects are described in Biblical verses and appear in mummies from Ancient Egypt. Those infected with Mycobacterium tuberculosis, which causes TB, can now be cured thanks to modern health advancements —…